Ipsen Appoints Gwenan White as Executive Vice President, Communications and Public Affairs
Gwenan White, Executive Vice President, Communications and Public Affairs, Ipsen (Photo: Business Wire)
Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Gwenan White as Executive Vice President, Communications and Public Affairs, effective March 2021. Based in Boulogne, France, she will be responsible for designing, implementing and managing the communications and public affairs strategy for Ipsen at global level, reporting directly to David Loew, CEO, Ipsen. Gwenan will serve on the Executive Leadership Team. Along with the ELT, we are very pleased to welcome Gwenan to Ipsen. She will be critical to the implementation of our new strategy, Focus. Together. For patients society
FOR MEDICAL BUSINESS/INDUSTRY TRADE MEDIA ONLY
The Mundipharma network of independently associated companies today announced two new appointments to their Executive Committee –
Julie Dehaene-Puype as
Erik Nordkamp as
– both reporting into Marc Princen, Chief Executive Officer.
Speaking of the appointments, Marc Princen commented,
“I am delighted to welcome Julie and Erik as highly experienced pharmaceutical leaders to complete our global organisation. They join us during a pivotal year for some of our pipeline assets as we continue to increase access to healthcare for many of the world’s most challenging diseases.”
Julie Dehaene-Puype is joining Mundipharma with over 20 years’ industry experience from Takeda, Merck and Schering Plough, where she has held strategic and operational roles at country, regional and global level across the US, Europe and Canada. Julie joins Mundipharma from Takeda where she was recently General Manager of France. Her role at Mundiph
Carlyle leads $123m round in Shanghai-based biopharma firm Abbisko Premium
Abbisko Therapeutics, a Shanghai-based biopharmaceutical firm, announced on Friday the completion of a Series D funding round at $123 million to advance the startup’s clinical programmes and to expand its portfolio in the discovery and preclinical development stages.
Continue reading this story with a subscription to DealStreetAsia.
Contact us for corporate subscriptions at subs@dealstreetasia.com.
Sign up for our newsletter - The Daily Brief Opt out of receiving The Daily Brief in your inbox everyday
REGISTER stories left placeholder You have one free story left this month. You have stories left placeholder free stories left this month.
January 8, 2021
HOMECorp was founded in 1988 by a dedicated group of community volunteers who saw the need to preserve affordability in Montclair. Since its founding, over 30 years ago, HOMECorp has developed nearly 200 units of affordable rental and owned housing in Montclair. HOMECorp also has a counseling department that offers first-time buyer workshops, foreclosure prevention services, and post-closing ownership support. HOMECorp creates and maintains housing that preserves economic diversity and ignites community revitalization while fostering financial empowerment.
Two new Trustees, Deb Morrone-Collela and Carmel Loughman, will be joining HOMECorp’s Board January 1, 2021.
Deborah Morrone-Colella joined The Seeing Eye in 2014 where she is the Director of Donor & Public Relations. She oversees all fundraising and communications programs.
DGAP-News: Immun .
DGAP-News: Immune Regulation Limited: Immune Regulation appoints New Chairman and builds out Senior Management Team with standout industry professionals in the US
vom 17.12.2020, 09:00 Uhr
Bild: pixabay.com
DGAP-News: Immune Regulation Limited / Key word(s): Personnel
Immune Regulation Limited: Immune Regulation appoints New Chairman and builds out Senior Management Team with standout industry professionals in the US
17.12.2020 / 09:00
The issuer is solely responsible for the content of this announcement.
Immune Regulation appoints New Chairman and builds out Senior Management Team with standout industry professionals in the US
(London UK, New Orleans US, 17 December, 2020) Immune Regulation Ltd, a US and UK based clinical stage biotechnology company announced today a series of appointments to build out the Board and leadership team that will work alongside Jonathan Rigby, Group CEO of Immune Regulation, in advancing the development of its fir